Rectal Cancer Clinical Trial
— TAPOfficial title:
A Prospective Randomized Clinical Trial Comparing the Transversus Abdominis Plane Block (TAP) Versus Epidural Anesthesia For Enhanced Recovery Pathway Perioperative Management of Pain in Elective Colorectal Surgery
Verified date | May 2017 |
Source | Saint Joseph Mercy Health System |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary outcome for this study is the Numeric Pain Score (NPS) for elective patients undergoing elective colorectal surgery that have been randomized to transversus abdominis plane block or epidural anesthesia for the management of perioperative pain in elective colorectal surgery.
Status | Active, not recruiting |
Enrollment | 185 |
Est. completion date | October 2018 |
Est. primary completion date | July 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients undergoing elective open and minimally invasive (laparoscopic and robotic) colon and rectal surgery for colorectal neoplasia, diverticulitis, and other diseases of the colon and rectum; - Surgical procedure either through standard open or minimal invasive approach (laparoscopic or robotic); - Patients > 18 years of age; - Able to provide informed written consent - Patients capable of completing questionnaires at the time of consent Exclusion Criteria: - Documented allergic reaction to morphine, hydromorphone, lidocaine, bupivicaine and/or fentanyl; - Contra-indication to placement of epidural catheter (spinal stenosis, spinal fusion, elevated INR, anticoagulation, patient refusal, etc) or TAP block (patient refusal); - Urgent or emergent surgery precluding epidural catheter placement or TAP block; - Systemic Infection contraindicating epidural catheter placement or TAP block; - Unwillingness to participate in follow up assessments; - Prisoners - Pregnant women |
Country | Name | City | State |
---|---|---|---|
United States | Saint Joseph Mercy Hospital | Ann Arbor | Michigan |
Lead Sponsor | Collaborator |
---|---|
Saint Joseph Mercy Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient use of supplemental narcotic analgesia post-operative day 1 | Measured in morphine equivalents | Post-operative day 1 | |
Other | Patient use of supplemental narcotic analgesia post-operative day 2 | Measured in morphine equivalents | Post-operative day 2 | |
Other | Patient use of supplemental narcotic analgesia post-operative day 3 | Measured in morphine equivalents | Post-operative day 3 | |
Primary | Post-operative pain control day 1 using the numeric pain scale | Measured by patient using the numeric pain scale | Post-operative day 1 | |
Primary | Post-operative pain control day 2 using the numeric pain scale | Measured by patient using the numeric pain scale | Post-operative day 2 | |
Primary | Post-operative pain control day 3 using the numeric pain scale | Measured by patient using the numeric pain scale | Post-operative day 3 | |
Secondary | Overall benefits of analgesia treatment post-operative day 1 | Measured by patient completing the Overall Benefits of Analgesia Score survey | Post-operative day 1 | |
Secondary | Overall benefits of analgesia treatment post-operative day 2 | Measured by patient completing the Overall Benefits of Analgesia Score survey | Post-operative day 2 | |
Secondary | Overall benefits of analgesia treatment post-operative day 3 | Measured by patient completing the Overall Benefits of Analgesia Score survey | Post-operative day 3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |